

ASX Announcement

19th December 2023

## **\$6.9m R&D tax incentive received**

Genetic Signatures [ASX:GSS] (“GSS” or the “Company”), a global molecular diagnostics company, is pleased to announce that it has received a refund from the Australian Taxation Office under its Research and Development (“R&D”) tax incentive program in the amount of \$6,877,061.

The R&D tax incentive is an Australian Government program under which companies receive cash refunds for eligible Australian and international R&D activities during the financial year ended 30 June 2023.

### **Authorisation and Additional Information**

This announcement was authorised by the Board of Directors of Genetic Signatures Limited.

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us as below:

**Dr John Melki**  
**Managing Director and**  
**Chief Executive Officer**  
[john.melki@geneticsignatures.com](mailto:john.melki@geneticsignatures.com)  
T: +61 (0)2 9870 7580

**Karl Pechmann**  
**Chief Financial and Operating Officer**  
**and Company Secretary**  
[karl.pechmann@geneticsignatures.com](mailto:karl.pechmann@geneticsignatures.com)

**About Genetic Signatures Limited:** Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures’ proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen™* respiratory kits and the growing interest in its gastroenteritis products to further commercialise its **3base®** technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.